Hemolytic-uremic syndrome historical perspective
Hemolytic-uremic syndrome Microchapters |
Differentiating Hemolytic-uremic syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hemolytic-uremic syndrome historical perspective On the Web |
American Roentgen Ray Society Images of Hemolytic-uremic syndrome historical perspective |
Hemolytic-uremic syndrome historical perspective in the news |
Risk calculators and risk factors for Hemolytic-uremic syndrome historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Historical Perspective
Discovery
- HUS was first described by Gasser and colleagues in paper published in 1955[1][2] .
- In 1983, Karmali and colleagueswas the first to discover the association between Escherichia coli and the development of HUS[2].
- The association between Shiga-toxin-producing bacteria and HUS was made 35 years ago[2].
- In [year], membrane cofactor protein (MCP), complement factor H (CFH) and factor I (IF) mutations were implicated in the pathogenesis of non–Shiga toxin–associated HUS[3]
Outbreaks
There have been several outbreaks of HUS, which are summarized below:
Shiga toxin-producing (STEC) Escherichia coli O157
Landmark Events in the Development of Treatment Strategies
In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].
Impact on Cultural History
Famous Cases
The following are a few famous cases of disease name:
References
- ↑ A. Schieppati, P. Ruggenenti, R. P. Cornejo, F. Ferrario, G. Gregorini, P. Zucchelli, E. Rossi & G. Remuzzi (1992). "Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome". Journal of the American Society of Nephrology : JASN. 2 (11): 1640–1644. PMID 1610985. Unknown parameter
|month=
ignored (help) - ↑ 2.0 2.1 2.2 Phillip I. Tarr, Carrie A. Gordon & Wayne L. Chandler (2005). "Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome". Lancet (London, England). 365 (9464): 1073–1086. doi:10.1016/S0140-6736(05)71144-2. PMID 15781103. Unknown parameter
|month=
ignored (help) - ↑ Jessica Caprioli, Marina Noris, Simona Brioschi, Gaia Pianetti, Federica Castelletti, Paola Bettinaglio, Caterina Mele, Elena Bresin, Linda Cassis, Sara Gamba, Francesca Porrati, Sara Bucchioni, Giuseppe Monteferrante, Celia J. Fang, M. K. Liszewski, David Kavanagh, John P. Atkinson & Giuseppe Remuzzi (2006). "Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome". Blood. 108 (4): 1267–1279. doi:10.1182/blood-2005-10-007252. PMID 16621965. Unknown parameter
|month=
ignored (help)